{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:39:35Z","timestamp":1785893975125,"version":"3.56.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"abstract":"\n Importance<\/jats:title>\n \n Inhibiting\n O<\/jats:italic>\n -linked\n N<\/jats:italic>\n -acetylglucosaminidase (OGA) is hypothesized to slow accumulation of aggregated, hyperphosphorylated tau and neurofibrillary tangle formation.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the efficacy and safety of the potent oral OGA inhibitor ceperognastat in early symptomatic Alzheimer disease (AD).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This double-blind, randomized, placebo-controlled phase 2 study was conducted at 72 sites in 5 countries from September 2021 to August 2024, with a posttreatment observational extension period through May 2025. The primary outcome population comprised participants with early symptomatic AD and biomarker evidence of tau pathology, including low to medium baseline tau levels (excluding individuals with high levels), as measured by positron emission tomography (PET) with flortaucipir F18.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Participants were randomized 1:1:1 to receive once-daily, oral ceperognastat at doses of 0.75 mg (n\u2009=\u2009110) or 3 mg (n\u2009=\u2009108) or placebo (n\u2009=\u2009108).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was change in Integrated AD Rating Scale (iADRS) score. The success criterion was a 60% or greater probability of achieving greater than or equal to 25% slower progression vs placebo using a bayesian probabilistic disease progression model. The 6 secondary outcomes were Alzheimer's Disease Assessment Scale\u2013Cognitive Subscale, 13-item version; Alzheimer\u2019s Disease Cooperative Study\u2013Activities of Daily Living scale; Clinical Dementia Rating\u2013Sum of Boxes; Mini-Mental State Examination; tau PET; and volumetric magnetic resonance imaging.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 327 randomized participants (mean age, 73.4 years; 201 [61.5%] females), 259 (87 receiving ceperognastat 0.75 mg, 86 receiving ceperognastat 3 mg, and 86 receiving placebo) with low to medium baseline tau levels were included in the primary outcome population (mean age, 74.3 years; 161 [62.2%] females). In this population, no clinically meaningful benefit vs placebo was observed for the primary end point (iADRS score) at 100 weeks: posterior mean change from baseline was \u22128.39 with ceperognastat 0.75 mg, \u221213.27 with ceperognastat 3 mg, and \u221210.07 with placebo. The disease progression ratio relative to placebo was 0.84 (95% credible interval [CrI], 0.66-1.04) for the ceperognastat 0.75 mg group and 1.32 (CrI, 1.10-1.58) for the ceperognastat 3 mg group, corresponding to 16% less and 32% greater progression, respectively. No benefits were demonstrated for secondary clinical end points. From baseline to 76 weeks, least-squares mean change in standardized uptake value ratio on PET showed a statistically significantly smaller increase (\n P<\/jats:italic>\n \u2009=\u2009.04) vs placebo only for the ceperognastat 3 mg group in the lateral temporal lobe. Volumetric magnetic resonance imaging showed less whole brain volume loss in participants treated with ceperognastat vs placebo (43.2% [ceperognastat 0.75 mg] and 49.5% [ceperognastat 3 mg] less vs placebo; both\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). The ceperognastat 3 mg group had more serious (ceperognastat 0.75 mg: n\u2009=\u200913 [12.0%]; ceperognastat 3 mg: n\u2009=\u200929 [26.4%]; placebo: n\u2009=\u200917 [15.7%]) and severe (ceperognastat 0.75 mg: n\u2009=\u20097 [6.5%]; ceperognastat 3 mg: n\u2009=\u200915 [13.6%]; placebo: n\u2009=\u20097 [6.5%]) treatment-emergent adverse events.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Ceperognastat did not slow disease progression of early symptomatic AD.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05063539<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.12768","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:30:15Z","timestamp":1783960215000},"source":"Crossref","is-referenced-by-count":2,"title":["Ceperognastat in Early Symptomatic Alzheimer Disease"],"prefix":"10.1001","author":[{"given":"Adam S.","family":"Fleisher","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Munsie","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Mancini","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Ju","family":"Cheng","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Guo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Nuthall","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Svaldi","family":"Otero","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Kotari","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kielbasa","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hutton","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslaw","family":"Brys","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin J.","family":"Mergott","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mintun","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"5","key":"joi260079r1","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer\u2019s disease facts and figures.","volume":"20","author":"Alzheimer\u2019s Association","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"joi260079r2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease.","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"joi260079r3","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.70176","article-title":"Alzheimer\u2019s disease: treatment challenges for the future.","volume":"169","author":"Hardy","year":"2025","journal-title":"J Neurochem"},{"issue":"12","key":"joi260079r4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: current status and future directions.","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"joi260079r5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13195-021-00880-x","article-title":"Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals.","volume":"13","author":"Biel","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"joi260079r6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study.","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol"},{"issue":"524","key":"joi260079r7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5732","article-title":"Prospective longitudinal atrophy in Alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET.","volume":"12","author":"La Joie","year":"2020","journal-title":"Sci Transl Med"},{"issue":"8","key":"joi260079r8","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","article-title":"Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging.","volume":"78","author":"Ossenkoppele","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1-2","key":"joi260079r9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0006-8993(89)91396-6","article-title":"Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer\u2019s disease.","volume":"477","author":"Bancher","year":"1989","journal-title":"Brain Res"},{"key":"joi260079r10","doi-asserted-by":"publisher","first-page":"20833","DOI":"10.1038\/srep20833","article-title":"Abnormal tau induces cognitive impairment through two different mechanisms: synaptic dysfunction and neuronal loss.","volume":"6","author":"Di","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"joi260079r11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12974-022-02567-y","article-title":"Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer\u2019s disease.","volume":"19","author":"Dong","year":"2022","journal-title":"J Neuroinflammation"},{"issue":"2","key":"joi260079r12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1152\/physrev.00043.2019","article-title":"Role of O-linked N-acetylglucosamine protein modification in cellular (patho)physiology.","volume":"101","author":"Chatham","year":"2021","journal-title":"Physiol Rev"},{"issue":"6","key":"joi260079r13","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1038\/s41380-025-02943-z","article-title":"Brain O-GlcNAcylation: Bridging physiological functions, disease mechanisms, and therapeutic applications.","volume":"30","author":"Chen","year":"2025","journal-title":"Mol Psychiatry"},{"issue":"Pt 7","key":"joi260079r14","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1093\/brain\/awp099","article-title":"Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer\u2019s disease.","volume":"132","author":"Liu","year":"2009","journal-title":"Brain"},{"key":"joi260079r15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.neuropharm.2013.11.025","article-title":"Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.","volume":"79","author":"Graham","year":"2014","journal-title":"Neuropharmacology"},{"issue":"1","key":"joi260079r16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13024-017-0181-0","article-title":"Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.","volume":"12","author":"Hastings","year":"2017","journal-title":"Mol Neurodegener"},{"issue":"4","key":"joi260079r17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nchembio.797","article-title":"Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation.","volume":"8","author":"Yuzwa","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"12","key":"joi260079r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105411","article-title":"Understanding and exploiting the roles of O-GlcNAc in neurodegenerative diseases.","volume":"299","author":"Pratt","year":"2023","journal-title":"J Biol Chem"},{"issue":"4","key":"joi260079r19","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70020","article-title":"Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer\u2019s disease.","volume":"10","author":"Kielbasa","year":"2024","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"joi260079r20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2024.21972","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human participants.","volume":"333","author":"World Medical Association","year":"2025","journal-title":"JAMA"},{"issue":"22","key":"joi260079r21","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2025.4347","article-title":"CONSORT 2025 Statement: updated guideline for reporting randomized trials.","volume":"333","author":"Hopewell","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"joi260079r22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"issue":"18","key":"joi260079r23","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease.","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"joi260079r24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"joi260079r25","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12312","article-title":"Integrated Alzheimer\u2019s Disease Rating Scale: clinically meaningful change estimates.","volume":"8","author":"Wessels","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"joi260079r26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.14283\/jpad.2015.82","article-title":"A combined measure of cognition and function for clinical trials: the integrated Alzheimer\u2019s Disease Rating Scale (iADRS).","volume":"2","author":"Wessels","year":"2015","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"joi260079r27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.14283\/jpad.2024.134","article-title":"Longitudinal Phospho-tau217 predicts amyloid positron emission tomography in asymptomatic Alzheimer\u2019s disease.","volume":"11","author":"Rissman","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"joi260079r28","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf433","article-title":"GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.","author":"Maceski","year":"2025","journal-title":"Brain"},{"issue":"21","key":"joi260079r29","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1002\/sim.7811","article-title":"A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer\u2019s disease.","volume":"37","author":"Wang","year":"2018","journal-title":"Stat Med"},{"issue":"3","key":"joi260079r30","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/pst.2285","article-title":"Natural cubic splines for the analysis of Alzheimer\u2019s clinical trials.","volume":"22","author":"Donohue","year":"2023","journal-title":"Pharm Stat"},{"issue":"6","key":"joi260079r31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.117.200691","article-title":"Test-retest reproducibility for the tau PET imaging agent flortaucipir F 18.","volume":"59","author":"Devous","year":"2018","journal-title":"J Nucl Med"},{"issue":"2","key":"joi260079r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100456","article-title":"Synaptic toxicity of OGA inhibitors and the failure of ceperognastat.","volume":"13","author":"Meade","year":"2026","journal-title":"J Prev Alzheimers Dis"},{"issue":"7","key":"joi260079r33","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41582-023-00822-1","article-title":"Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration.","volume":"19","author":"Patani","year":"2023","journal-title":"Nat Rev Neurol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2851734\/jama_fleisher_2026_oi_260079_1783697609.33444.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:30:16Z","timestamp":1783960216000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2851734"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":33,"URL":"https:\/\/doi.org\/10.1001\/jama.2026.12768","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,13]]}}}